

Garyleda Ferrari-Dileo, Ph.D

Legal Division Patents & Trademarks Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064-6008

Telephone: FAX:

(847) 935-1729

(847) 938-2623

FACSIMILE COVER SHEET

DATE:

November 10, 2004

TO:

Francine P. Mercer Group Art Unit 1623

FROM:

Gabryleda Ferrari-Dileo, Ph.D.

Patents and Trademarks

D-0377, AP6A-1.

Telephone: (847) 935-4314

PHONE NUMBER OF TELECOPY MACHINE: 571-273-0541

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 12

MESSAGE:

RE:

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR

SUBTYPE 1 (VR1) RECEPTOR

Transmitting:

Transmittal Letter - 1 pg. (in duplicate)

Response to Notice of Non-Compliant Amendment - 9 pgs.

THIS TRANSMISSION IS INTENDED ONLY FOR THE INDIVIDUAL(S) TO WHOM IT IS ADDRESSED.

It may contain confidential information, attorney work product, or other privileged material. If you are not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at (847) 935-7562 and return the transmission to us at the address listed above. OAbbott Laboratories, 1991. All rights reserved. IF YOU DO NOT RECEIVE ALL PAGES AS INDICATED, PLEASE CALL (847) 935-7562

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For. FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

Certificate of Facsimile Transmission under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Commissioner for Patents
Attn: Examiner Francine P. Mercer

Group Art Unit 1623 Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

Whole -

Date

11/10/04

TRANSMITTAL LETTER

Commissioner for Patents Attn: Francine P. Mercer Group Art Unit 1623 Alexandria, VA 22313-1450

Dear Sir/Madame:

Enclosed herewith for the patent application identified above, entitled FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR are the following:

1. Response to Notice of Non-Compliant Amendment (9 Pages)

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

Respectfully submitted, Chih-Hung Lee, et al.

ABBOTT LABORATORIES Telephone: (847) 935-4314

Facsimile: (847) 938-2623

Gábryleda Ferrari-Dileo Registration No. 55,174 Attorney for Applicants

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR

SUBTYPE 1 (VR1) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

Certificate of Facsimile Transmission under 37 CFR §1.8(a):

I.hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Commissioner for Patents

Attn: Examiner Francine P. Mercer Group Art Unit 1623

Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

11/10/04

TRANSMITTAL LETTER

Commissioner for Patents Attn: Francine P. Mercer Group Art Unit 1623 Alexandria, VA 22313-1450

Dear Sir/Madame:

Enclosed herewith for the patent application identified above, entitled FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR are the following:

I. Response to Notice of Non-Compliant Amendment (9 Pages)

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

Respectfully submitted, Chih-Hung Lee, et al.

ABBOTT LABORATORIES

Telephone: (847) 935-4314

Facsimile: (847) 938-2623

Gábryleda Ferrari-Dileo Registration No. 55,174

Attorney for Applicants

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR

SUBTYPE I (VRI) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

Certificate of Facsimile Transmission under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Commissioner for Patents

Attn: Examiner Francine P. Mercer Group Art Unit 1623

Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT (37 CFR 1.121)

Commissioner for Patents Attn: Francine P. Mercer Group Art Unit 1623 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice of Non-Compliant Amendment, dated October 26, 2004, in the patent application identified above, please find the corrected section of the non-compliant amendment as follows:

Corrected Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 2 of this paper.